Vise Technologies Inc. decreased its position in shares of Zoetis Inc. (NYSE:ZTS – Get Rating) by 46.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,155 shares of the company’s stock after selling 1,005 shares during the quarter. Vise Technologies Inc.’s holdings in Zoetis were worth $218,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently modified their holdings of the company. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in shares of Zoetis by 430.8% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after buying an additional 112 shares during the period. Financial Management Professionals Inc. increased its stake in Zoetis by 117.4% during the first quarter. Financial Management Professionals Inc. now owns 150 shares of the company’s stock worth $28,000 after acquiring an additional 81 shares during the last quarter. Mystic Asset Management Inc. purchased a new stake in Zoetis in the fourth quarter valued at $37,000. Worth Asset Management LLC acquired a new position in shares of Zoetis in the 1st quarter valued at $26,000. Finally, Rather & Kittrell Inc. purchased a new position in shares of Zoetis during the 4th quarter worth $42,000. Hedge funds and other institutional investors own 91.05% of the company’s stock.
Insider Buying and Selling at Zoetis
In related news, EVP Roxanne Lagano sold 4,334 shares of Zoetis stock in a transaction on Monday, June 27th. The shares were sold at an average price of $175.00, for a total transaction of $758,450.00. Following the sale, the executive vice president now directly owns 23,687 shares in the company, valued at approximately $4,145,225. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Roxanne Lagano sold 4,334 shares of the firm’s stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $175.00, for a total transaction of $758,450.00. Following the transaction, the executive vice president now owns 23,687 shares in the company, valued at approximately $4,145,225. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kristin C. Peck sold 9,689 shares of the stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $180.00, for a total value of $1,744,020.00. Following the completion of the sale, the chief executive officer now directly owns 39,743 shares of the company’s stock, valued at $7,153,740. The disclosure for this sale can be found here. Insiders have sold a total of 16,501 shares of company stock worth $2,949,073 over the last ninety days. Corporate insiders own 0.12% of the company’s stock.
Zoetis Stock Performance
Zoetis (NYSE:ZTS – Get Rating) last released its earnings results on Thursday, August 4th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.22 by ($0.02). The company had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.03 billion. Zoetis had a return on equity of 49.03% and a net margin of 26.14%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.19 earnings per share. On average, research analysts predict that Zoetis Inc. will post 5.01 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research firms have commented on ZTS. Piper Sandler initiated coverage on shares of Zoetis in a research report on Monday, July 11th. They issued an “overweight” rating and a $205.00 target price on the stock. Stifel Nicolaus decreased their price objective on shares of Zoetis from $275.00 to $225.00 and set a “buy” rating on the stock in a report on Friday, June 24th. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Friday, August 5th. The Goldman Sachs Group decreased their price target on Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a research note on Thursday, July 21st. Finally, StockNews.com raised Zoetis from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 9th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus price target of $224.00.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
- Get a free copy of the StockNews.com research report on Zoetis (ZTS)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It’s a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.